Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Oxygen uptake efficiency plateau, measured during the cardiopulmonary exercise test, offers a novel method for evaluating gas exchange abnormalities in patients with idiopathic pulmonary hypertension, Chinese researchers report.
An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps.
When a large blood clot was discovered attached to the end of a catheter inside the right atrial chamber of a patient's heart, doctors faced a daunting challenge.
RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.
A first-of-its-kind yoga exercise program has been developed by Henry Ford Hospital for patients living with pulmonary hypertension, a chronic lung disease that afflicts women at least two times more than men.
We start with birth and we collect the cells after C-section. The reason for that is we have to have the mother sign a consent letter that she is donating the placenta and, on top of that, we have to have a blood sample from the mother to test for any viral contamination.
Surgery patients are much less likely to get a blood clot in the lower extremities or lungs if they receive preventive treatment based on their individual clotting risk, in addition to walking soon after the operation.
After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.
In patients with congestive heart failure, obesity and a larger waist size have paradoxically been associated with a better prognosis in the prior investigations. This effect, known as the obesity paradox phenomenon, is now being demonstrated in patients with severe pulmonary hypertension.
N-terminal pro-brain natriuretic peptide remains a valid predictor in patients with pulmonary arterial hypertension who have concomitant renal dysfunction, say researchers.
Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers.
Researchers have identified clinical features that could help predict which patients with systemic sclerosis are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment.
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.
The last decade has seen a strong movement towards the use of various quality measurements to grade medical care. In surgery, 30-day mortality is one of the most common benchmarks. We wanted to determine if patterns of postoperative mortality showed any signs that the process of measuring medical care might actually alter how (and when) care is provided or withdrawn.
Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).
In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans.
Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.
Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.
EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.